Laboratory Corporation of America Holdings
NYSE:LH
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
212.22
290.93
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Laboratory Corporation of America Holdings
Laboratory Corporation of America Holdings, commonly known as LabCorp, stands as a formidable player in the world of healthcare diagnostics. Emerging from a confluence of scientific innovation and business acumen, LabCorp has carved a niche within the intricate fabric of healthcare services. Since its inception, the company has excelled in offering a comprehensive suite of laboratory-based tests and services, empowering physicians and healthcare providers with critical insights needed for effective patient diagnosis and management. With its headquarters in Burlington, North Carolina, LabCorp operates a vast network of laboratories and patient service centers across the nation, providing services that range from routine blood work to sophisticated genomic testing.
The essence of LabCorp’s business model lies in seamless integration across the healthcare continuum, driving both operational efficiency and profitability. Fundamentally, the company generates revenue by performing diagnostic tests on patient specimens, serving hospitals, managed care organizations, physician offices, and governmental agencies. As healthcare systems evolve towards precision medicine, LabCorp has harnessed emerging technologies and innovations like genomic testing to enhance its service offerings. This expansion not only aligns with changing healthcare paradigms but also fortifies its market leadership. By continually investing in research and development, LabCorp keeps its services at the cutting edge, ensuring steady growth and resilience in an ever-changing healthcare landscape.
Laboratory Corporation of America Holdings, commonly known as LabCorp, stands as a formidable player in the world of healthcare diagnostics. Emerging from a confluence of scientific innovation and business acumen, LabCorp has carved a niche within the intricate fabric of healthcare services. Since its inception, the company has excelled in offering a comprehensive suite of laboratory-based tests and services, empowering physicians and healthcare providers with critical insights needed for effective patient diagnosis and management. With its headquarters in Burlington, North Carolina, LabCorp operates a vast network of laboratories and patient service centers across the nation, providing services that range from routine blood work to sophisticated genomic testing.
The essence of LabCorp’s business model lies in seamless integration across the healthcare continuum, driving both operational efficiency and profitability. Fundamentally, the company generates revenue by performing diagnostic tests on patient specimens, serving hospitals, managed care organizations, physician offices, and governmental agencies. As healthcare systems evolve towards precision medicine, LabCorp has harnessed emerging technologies and innovations like genomic testing to enhance its service offerings. This expansion not only aligns with changing healthcare paradigms but also fortifies its market leadership. By continually investing in research and development, LabCorp keeps its services at the cutting edge, ensuring steady growth and resilience in an ever-changing healthcare landscape.
Strong Revenue Growth: Labcorp reported Q3 revenue of $3.6 billion, up 8.6% from last year, driven by 6.2% organic growth, 1.7% acquisitions, and 0.7% currency impact.
Margin Expansion: Enterprise margin improved by 100 basis points, with Diagnostics margin up 110 basis points and BLS margin up 20 basis points.
Double-Digit EPS Growth: Adjusted EPS reached $4.18, an increase of 19% year-over-year.
Raised EPS Guidance: Full-year adjusted EPS guidance was narrowed and the midpoint raised by $0.05, now at $16.15 to $16.50.
Strong Cash Flow: Free cash flow grew to $281 million this quarter, up by $119 million versus last year, and FY25 free cash flow guidance was raised.
Portfolio Streamlining: Labcorp is consolidating sites and divesting about $50 million in annual Early Development revenue, expected to slightly improve operating income.
Strategic M&A Progress: Multiple lab asset acquisitions were completed or agreed upon, with more in the pipeline and integration progressing as planned.
AI and Specialty Testing: Investments in AI, digital pathology, and specialty areas like oncology and neurology are supporting innovation and efficiency.
